Business
Drugs giant AstraZeneca’s major setback as bad trial results wipe £10bn from value
ASTRAZENECA investors felt the pain yesterday as a major setback for a key lung cancer treatment wiped nearly £10billion from the company’s market value.
Daily Express :: Finance Feed
Comments (0)